---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-072708"
form_type: "8-K"
ticker: "SNGX"
cik: "0000812796"
company_name: "SOLIGENIX, INC."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:35:21.454662+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Soligenix SGX945 Phase 2a: 40% improvement in Behçet's ulcers, matching Otezla's 37%

## Summary
- SGX945 achieved 40% improvement vs placebo on primary endpoint at Week 4; apremilast (Otezla) had 37% improvement.
- 7 of 8 patients reported benefit; 1 patient's skin ulcer resolved; no treatment-related adverse events.
- Improvement sustained at Week 8 (32%) despite stopping treatment at Week 4; Otezla continuous dosing had 41%.
- Company plans reformulation for home subcutaneous injection and a placebo-controlled Phase 2 study.
- Behçet's Disease affects ~18,000 in US; SGX945 well-tolerated with no GI side effects vs Otezla.

## SEC filing metadata
- accession: 0001104659-25-072708
- form_type: 8-K
- ticker: SNGX
- cik: 0000812796
- company_name: SOLIGENIX, INC.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/812796/000110465925072708/0001104659-25-072708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/812796/000110465925072708/tm2522246d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-072708
- JSON: https://secwatch.observer/filing/0001104659-25-072708.json
- Plain text: https://secwatch.observer/filing/0001104659-25-072708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.